Amendment: SEC Form SC 13G/A filed by Revvity Inc.
$RVTY
Biotechnology: Laboratory Analytical Instruments
Industrials
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2025 | $115.00 | Neutral → Buy | UBS |
| 1/10/2025 | $130.00 | Outperform → Mkt Perform | Bernstein |
| 12/13/2024 | $138.00 | Neutral → Buy | BofA Securities |
| 10/15/2024 | $125.00 → $140.00 | Equal Weight → Overweight | Barclays |
| 8/28/2024 | $130.00 | Equal Weight | Wells Fargo |
| 7/8/2024 | $125.00 | Outperform | Leerink Partners |
| 6/3/2024 | $115.00 | Hold | Jefferies |
| 1/16/2024 | $105.00 → $125.00 | Buy → Neutral | UBS |
8-K - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
DEFA14A - REVVITY, INC. (0000031791) (Filer)
Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: Bank of America Global Healthcare Conference 2025 Tuesday, May 13, 2025 9:20 a.m. PT - Max Krakowiak, senior vice president and chief financial officer Goldman Sachs 46th Annual Global Healthcare Conference Tuesday, June 10, 2025 8:00 a.m. ET - Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will b
Revenue of $665 million; 2% reported growth; 4% organic growth GAAP EPS of $0.35; Adjusted EPS from continuing operations of $1.01 Reaffirms full year 2025 organic growth and adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operating profit margin from continu
The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detec
UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00
Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00
BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00
Revenue of $665 million; 2% reported growth; 4% organic growth GAAP EPS of $0.35; Adjusted EPS from continuing operations of $1.01 Reaffirms full year 2025 organic growth and adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operating profit margin from continu
The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detec
Revvity, Inc. (NYSE:RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G - REVVITY, INC. (0000031791) (Subject)